ArticleWorld journal of urology2025
The efficacy of prostate health index (PHI) in predicting pathological progression in low-risk localized prostate cancer cases under active surveillance protocol.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review).International journal of oncology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the efficacy of the Prostate Health Index (PHI) in predicting pathological progression under an active surveillance protocol in low-risk localized prostate cancer (PC) cases. MATERIALS AND
methodsPre-biopsy blood samples were collected from patients who underwent prostate biopsy as part of another study since January 2015, centrifuged, and stored in refrigerators at -20/-80 °C. PHI values were calculated for 77 patients who met active surveillance criteria between January 2015 and January 2022. PHI values in serum samples of groups that showed and did not show progression after control biopsy were compared according to the initial biopsy pathology. The relationship between PHI and pathological progression was evaluated.
resultsA total of 77 patients who met the study criteria were included in the study. Progression was observed in 28 patients during control biopsy, while no progression was observed in 49 patients. In the group showing progression on the first biopsy, the PHI value was 82.06 ± 74.82, while in the group without progression, the PHI value was 50.21 ± 28.18 (p = 0.041). In the group showing progression on the second biopsy, the PHI value was 115.85 ± 109.6, while in the group without progression, the PHI value was 79.29 ± 80.97 (p = 0.005). ROC analysis showed the diagnostic value of PHI values at the time of diagnosis in predicting progression (AUC: 0.641, 95% CI 0.510-0.771, p = 0.034).
conclusionConsidering the ease of measurement and differences in MP-MRI interpretation, PHI value is a useful, beneficial and highly predictive biomarker for predicting progression in patients under active surveillance, even when used alone.
Indexed as
Identifiers
40650759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.